MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-20-3863

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2021

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.

Hu Yongxian, Zhou Yali, Zhang Mingming, Ge Wengang, Li Yi, Yang Li, Wei Guoqing, Han Lu, Wang Hao, Yu Shuhui, Chen Yi, Wang Yanbin, He Xiaohong, Zhang Xingwang, Gao Ming, Yang Jingjing, Li Xiuju, Ren Jiangtao, Huang He

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, certain characteristics of autologous CAR-T cells can delay treatment availability. Relapse caused by antigen escape after single-targeted CAR-T therapy is another issue. Therefore, we aim to develop CRISPR-edited universal off-the-shelf CD19/CD22 dual-targeted CAR-T cells as a novel therapy for r/r ALL.

PATIENTS AND

METHODS

In this open-label dose-escalation phase I study, universal CD19/CD22-targeting CAR-T cells (CTA101) with a CRISPR/Cas9-disrupted TRAC region and CD52 gene to avoid host immune-mediated rejection were infused in patients with r/r ALL. Safety, efficacy, and CTA101 cellular kinetics were evaluated.

RESULTS

CRISPR/Cas9 technology mediated highly efficient, high-fidelity gene editing and production of universal CAR-T cells. No gene editing-associated genotoxicity or chromosomal translocation was observed. Six patients received CTA101 infusions at doses of 1 (3 patients) and 3 (3 patients) × 106 CAR+ T cells/kg body weight. Cytokine release syndrome occurred in all patients. No dose-limiting toxicity, GvHD, neurotoxicity, or genome editing-associated adverse events have occurred to date. The complete remission (CR) rate was 83.3% on day 28 after CTA101 infusion. With a median follow-up of 4.3 months, 3 of the 5 patients who achieved CR or CR with incomplete hematologic recovery (CR/CRi) remained minimal residual disease (MRD) negative.

CONCLUSIONS

CRISPR/Cas9-engineered universal CD19/CD22 CAR-T cells exhibited a manageable safety profile and prominent antileukemia activity. Universal dual-targeted CAR-T cell therapy may offer an alternative therapy for patients with r/r ALL.

Для цитирования: Hu Yongxian, Zhou Yali, Zhang Mingming, Ge Wengang, Li Yi, Yang Li, Wei Guoqing, Han Lu, Wang Hao, Yu Shuhui, Chen Yi, Wang Yanbin, He Xiaohong, Zhang Xingwang, Gao Ming, Yang Jingjing, Li Xiuju, Ren Jiangtao, Huang He. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. DOI: 10.1158/1078-0432.ccr-20-3863.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.